glp-1 shopping drug use cuts grocery spending by 6%, study finds How GLP-1 Drugs Are Cutting

The big advantage

The same goes for people who previously stopped GLP-1 therapy because of side effects and are considering trying again

The product names may change, but the desire to find the perfect weight loss pill or supplement is timeless

Clinicians may also review strength, activity, and protein intake when lean-mass preservation is a concern

doi: 10.1016/j.ejphar.2025.177953

A separate KFF analysis from March about Medicare Part D spending data from the Centers for Medicare & Medicaid Services found that gross Medicare spending on the three newest versions of GLP-1 diabetes medicines (Ozempic, Rybelsus and Mounjaro) that also have been approved for weight loss skyrocketed from $57 million in 2018 to $5.7 billion in 2022